

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

[gov.uk/mhra](https://www.gov.uk/mhra)

Decision Cover Letter

Decision of the licensing authority to:

grant a product specific waiver

MHRA-100927-PIP01-23

Scope of the Application

Active Substance(s)

Namulumab

Condition(s)

Treatment of sarcoidosis

Pharmaceutical Form(s)

Solution for injection

Route(s) of Administration

SUBCUTANEOUS USE

Name / Corporate name of the PIP applicant

Kinevant Sciences GmbH

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Kinevant Sciences GmbH submitted to the licensing authority on 10/03/2023 11:21 GMT an application for a Waiver

The procedure started on 10/07/2023 07:55 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to grant a product specific waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100927-PIP01-23

Of 09/08/2023 10:58 BST

On the adopted decision for Namilumab (MHRA-100927-PIP01-23) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Granting a waiver in all age groups for the listed condition(s)

This decision applies to a Waiver for Namilumab, Solution for injection , SUBCUTANEOUS USE .

This decision is addressed to Kinevant Sciences GmbH, Viaduktstrasse 8 , Basel, SWITZERLAND, CH-4051

ANNEX I

1. Waiver

1.1 Condition:

Treatment of sarcoidosis The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 18 years of age Pharmaceutical form(s): Solution for injection Route(s) of administration: SUBCUTANEOUS USE Reason for granting waiver: For the paediatric population from birth to less than 5 years of age : on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s). For the paediatric population from 5 years to less than 18 years of age: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Not applicable

2.2 Indication(s) targeted by the PIP:

Not applicable

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

Not applicable

2.4 Pharmaceutical Form(s):

Not applicable

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures		
Non-Clinical Studies		
Clinical Studies		
Extrapolation, Modeling & Simulation Studies		
Other Studies		
Other Measures		

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	
Date of completion of the paediatric investigation plan:	
Deferral of one or more studies contained in the paediatric investigation plan:	

